As many expected after announcing negative interim results on May 11, Genfit (NASDAQ:GNFT) has decided to discontinue the Phase 3 RESOLVE-IT study evaluating elafibranor in patients with nonalcoholic steatohepatitis (NASH).
The company’s “new strategy” will focus on developing elafibranor for primary biliary cholangitis (PBC) and growing its NIS4 business in NASH diagnostics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.